KR20140051944A - 탄키라제 억제제로서 사용하기 위한 4-피페리디닐 화합물 - Google Patents

탄키라제 억제제로서 사용하기 위한 4-피페리디닐 화합물 Download PDF

Info

Publication number
KR20140051944A
KR20140051944A KR20147003628A KR20147003628A KR20140051944A KR 20140051944 A KR20140051944 A KR 20140051944A KR 20147003628 A KR20147003628 A KR 20147003628A KR 20147003628 A KR20147003628 A KR 20147003628A KR 20140051944 A KR20140051944 A KR 20140051944A
Authority
KR
South Korea
Prior art keywords
oxo
pyrrolidin
ylmethyl
piperidin
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20147003628A
Other languages
English (en)
Korean (ko)
Inventor
크리스틴 히우-퉁 첸
노엘 친 친
루시안 브이. 디피에트로
지안메 판
마크 지 팔레르모
마이클 데이비드 슐츠
베이커리-배리 투레
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20140051944A publication Critical patent/KR20140051944A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR20147003628A 2011-07-13 2012-07-13 탄키라제 억제제로서 사용하기 위한 4-피페리디닐 화합물 Withdrawn KR20140051944A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507321P 2011-07-13 2011-07-13
US61/507,321 2011-07-13
PCT/IB2012/053613 WO2013008217A1 (en) 2011-07-13 2012-07-13 4 - piperidinyl compounds for use as tankyrase inhibitors

Publications (1)

Publication Number Publication Date
KR20140051944A true KR20140051944A (ko) 2014-05-02

Family

ID=46604017

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20147003628A Withdrawn KR20140051944A (ko) 2011-07-13 2012-07-13 탄키라제 억제제로서 사용하기 위한 4-피페리디닐 화합물

Country Status (21)

Country Link
US (2) USRE46942E1 (enExample)
EP (1) EP2731940B1 (enExample)
JP (1) JP5957077B2 (enExample)
KR (1) KR20140051944A (enExample)
CN (1) CN103797006B (enExample)
AP (1) AP2014007400A0 (enExample)
AU (1) AU2012282076A1 (enExample)
BR (1) BR112014000792A2 (enExample)
CA (1) CA2841932A1 (enExample)
CO (1) CO6880065A2 (enExample)
CR (1) CR20140071A (enExample)
DO (1) DOP2014000012A (enExample)
EA (1) EA201490272A1 (enExample)
ES (1) ES2548513T3 (enExample)
IL (1) IL230430A0 (enExample)
MA (1) MA35342B1 (enExample)
MX (1) MX2014000536A (enExample)
PH (1) PH12014500126A1 (enExample)
TN (1) TN2014000016A1 (enExample)
WO (1) WO2013008217A1 (enExample)
ZA (1) ZA201400374B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016006974A3 (en) * 2014-07-11 2016-07-21 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) * 2014-07-11 2016-07-21 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
US9914737B2 (en) 2014-07-11 2018-03-13 St Pharm Co., Ltd. Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
US10179785B2 (en) 2014-07-11 2019-01-15 St Pharm Co., Ltd. Imidazotriazinone or imidazopyrazinone derivatives, and use thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2731942B1 (en) * 2011-07-13 2015-09-23 Novartis AG Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Kras g12c之共價抑制劑
HUE037134T2 (hu) * 2013-08-07 2018-08-28 Merck Patent Gmbh Piperidin-karbamid-származékok
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
WO2015135461A1 (zh) * 2014-03-10 2015-09-17 四川海思科制药有限公司 取代的二氢苯并呋喃-哌啶-甲酮衍生物、其制备及用途
RU2016147727A (ru) 2014-05-07 2018-06-08 Мерк Патент Гмбх Гетероциклилбутанамидные производные
MX2018005515A (es) 2015-11-02 2018-08-01 Merck Patent Gmbh Derivados de 1,4-dicarbonil-piperidilo.
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AU2019392502A1 (en) 2018-12-03 2021-07-22 Merck Patent Gmbh 4-heteroarylcarbonyl-N-(phenyl or heteroaryl) piperidine-1-carboxamides as inhibitors of tankyrases
EP3898609A1 (en) 2018-12-19 2021-10-27 Shy Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN119390683A (zh) 2019-08-15 2025-02-07 黑钻治疗公司 炔基喹唑啉化合物
US20240041859A1 (en) * 2020-12-03 2024-02-08 Washington University Methods of treating and preventing kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
WO2000042025A1 (en) 1999-01-14 2000-07-20 Meiji Seika Kaisha, Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10056312A1 (de) 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
US7402580B2 (en) 2002-02-19 2008-07-22 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
ATE440825T1 (de) 2003-06-06 2009-09-15 Vertex Pharma Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
JP2007513154A (ja) 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
WO2006003150A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
KR20200019263A (ko) 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2008546843A (ja) 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
BRPI0710050A2 (pt) * 2006-04-25 2011-08-02 Lilly Co Eli composto, composição farmacêutica, e, intermediário
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
AU2008298948B2 (en) 2007-09-12 2014-09-04 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
EP2214675B1 (en) 2007-10-25 2013-11-20 Genentech, Inc. Process for making thienopyrimidine compounds
CN101854924A (zh) 2007-11-05 2010-10-06 诺瓦提斯公司 测量wnt活化以及治疗wnt相关癌症的方法和组合物
KR101179753B1 (ko) 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
JP5492183B2 (ja) 2008-03-27 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Parpおよびチューブリン重合阻害剤としてのテトラヒドロフェナントリジノンおよびテトラヒドロシクロペンタキノリノン
EP2731942B1 (en) * 2011-07-13 2015-09-23 Novartis AG Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016006974A3 (en) * 2014-07-11 2016-07-21 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A3 (en) * 2014-07-11 2016-07-21 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
US9914737B2 (en) 2014-07-11 2018-03-13 St Pharm Co., Ltd. Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
US10179785B2 (en) 2014-07-11 2019-01-15 St Pharm Co., Ltd. Imidazotriazinone or imidazopyrazinone derivatives, and use thereof

Also Published As

Publication number Publication date
EP2731940A1 (en) 2014-05-21
CA2841932A1 (en) 2013-01-17
EA201490272A1 (ru) 2014-05-30
WO2013008217A1 (en) 2013-01-17
JP2014522855A (ja) 2014-09-08
CO6880065A2 (es) 2014-02-28
DOP2014000012A (es) 2014-07-31
NZ620426A (en) 2015-08-28
ZA201400374B (en) 2014-10-29
CN103797006A (zh) 2014-05-14
BR112014000792A2 (pt) 2017-10-31
CR20140071A (es) 2014-10-16
MX2014000536A (es) 2014-12-05
AU2012282076A1 (en) 2014-02-27
TN2014000016A1 (en) 2015-07-01
ES2548513T3 (es) 2015-10-19
USRE46942E1 (en) 2018-07-10
PH12014500126A1 (en) 2014-02-24
EP2731940B1 (en) 2015-08-19
US9163003B2 (en) 2015-10-20
CN103797006B (zh) 2016-01-27
JP5957077B2 (ja) 2016-07-27
IL230430A0 (en) 2014-03-31
MA35342B1 (fr) 2014-08-01
US20150126513A1 (en) 2015-05-07
AP2014007400A0 (en) 2014-01-31

Similar Documents

Publication Publication Date Title
JP5957077B2 (ja) タンキラーゼ阻害剤として使用するための4−ピペリジニル化合物
US9181266B2 (en) 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
KR102912147B1 (ko) 치환된 피라졸로피리미딘 및 치환된 푸린 및 유비퀴틴-특이적-가공 프로테아제 1 (usp1) 억제제로서의 그의 용도
CA3204823A1 (en) Prmts inhibitors
AU2013331496B2 (en) Methylene linked quinolinyl modulators of ROR-gamma-t
US9957251B2 (en) Heterocyclic compound
EA032416B1 (ru) Соединения триазолопиримидина и их применения
WO2005105814A1 (en) Tetracyclic inhibitors of janus kinases
JP2021515767A (ja) Erk5阻害剤の同定及び使用
EP2731951A1 (en) 4-oxo-3,5,7,8-tetrahydro-4h-pyrano {4,3-d} pyrminidinyl compounds for use as tankyrase inhibitors
WO2016102493A1 (en) Imidazopyridine ezh2 inhibitors
AU2021289169B2 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
US9546173B2 (en) Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors
AU2019200726A1 (en) Methylene linked quinolinyl modulators of ROR-gamma-T
KR20250002409A (ko) Hpk1 억제제로서의 피리도[3,2-d]피리미딘
RU2833222C2 (ru) Замещенные пиразолопиримидины и замещенные пурины и их применение в качестве ингибиторов убиквитин-специфической процессирующей протеазы 1 (usp1)
NZ620426B2 (en) 4-piperidinyl compounds for use as tankyrase inhibitors
EA046513B1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140212

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid